The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

Baal, Juliette O.A.M. van; Vijver, Koen K. Van de; Algera, Marc Daniël; Aa, M.A. van der; Sonke, Gabe S.; Driel, W.J. van; Kenter, G.G.; Amant, Frédéric; Lok, Car

doi:10.1016/j.ygyno.2019.03.257

Cited by 7 publications

(6 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overwhelmingly high mortality of ovarian cancers is in part due to the aggressive nature of the disease coupled with the lack of screening strategies [39,42]. In particular, the 5-year survival for patients diagnosed with early (FIGO stage I) disease is >90%; recurrence rates for these patients are below 20% [43]. Screening is therefore widely believed to be key in reducing mortality from ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer

Stephens,

Hobbs,

Kang

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer remains the most lethal of gynecological malignancies, with the 5-year survival below 50%. Currently there is no simple and effective pre-surgical diagnosis or triage for patients with malignancy, particularly those with early-stage or low-volume tumors. Recently we discovered that CXCL10 can be processed to an inactive form in ovarian cancers and that its measurement has diagnostic significance. In this study we evaluated the addition of processed CXCL10 to a biomarker panel for the discrimination of benign from malignant disease. Multiple biomarkers were measured in retrospectively collected plasma samples (n = 334) from patients diagnosed with benign or malignant disease, and a classifier model was developed using CA125, HE4, Il6 and CXCL10 (active and total). The model provided 95% sensitivity/95% specificity for discrimination of benign from malignant disease. Positive predictive performance exceeded that of “gold standard” scoring systems including CA125, RMI and ROMA% and was independent of menopausal status. In addition, 80% of stage I-II cancers in the cohort were correctly identified using the multi-marker scoring system. Our data suggest the multi-marker panel and associated scoring algorithm provides a useful measurement to assist in pre-surgical diagnosis and triage of patients with suspected ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer

Stephens,

Hobbs,

Kang

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In recent years, minimally-invasive surgery (MIS) techniques have been increasingly used in gynecological oncology practice because of the several benefits reported with respect to the open approach [26][27][28][29][30][31][32]. In particular, MIS has been successfully employed in selected ROC patients presenting a lower incidence of morbidities, apparently without compromising their survival [33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Certelli,

Russo,

Palmieri

et al. 2023

Cancers

View full text Add to dashboard Cite

The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.

show abstract

“…In addition, the pathology findings determine the need for adjuvant therapy, making comprehensive surgical staging of EOC particularly important. [ 4 5 ] According to the International Federation of Gynecology and Obstetrics (FIGO), the optimal procedure includes total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, multiple peritoneal biopsies, diaphragmatic scrapings, and bilateral pelvic and para-aortic lymph node dissection. [ 6 7 ]…”

Section: Introductionmentioning

confidence: 99%

Comparison of Laparoscopy and Laparotomy in the Management of Early-stage Ovarian Cancer

Garcia

Moreno

Teixeira

et al. 2023

Gynecology and Minimally Invasive Therapy

View full text Add to dashboard Cite

Objectives: The objective of this study was to assess the feasibility of minimally invasive surgery for early-stage ovarian cancer (EOC) by comparing the surgical and survival outcomes between laparoscopy and laparotomy. Materials and Methods: This was a retrospective, single-center observational study that included all patients who underwent surgical staging for EOC by laparoscopy or laparotomy between 2010 and 2019. Results: Forty-nine patients were included; of which 20 underwent laparoscopy, 26 laparotomy, and three conversion from laparoscopy to laparotomy. No significant differences were observed between the two groups regarding operative time, number of lymph nodes dissected, or intraoperative tumor rupture rate, while estimated blood loss and transfusion requirements were lower in the laparoscopy group. The complication rate tended to be higher in the laparotomy group. Patients in the laparoscopy group had a faster recovery, with earlier urinary catheter and abdominal drain removal, shorter hospital stay, and a trend toward earlier tolerance of oral diet and mobilization. At a mean follow-up of 45.7 months, 14 patients had disease recurrence, with no differences in the mean progression-free survival between the two groups (36 months for laparoscopy vs. 35.5 months for laparotomy, P = 0.22). Conclusion: Laparoscopic surgery performed by a trained gynecological oncologist is a safe and effective surgical approach for comprehensive staging of EOC, with the additional benefits of a faster recovery compared to laparotomy.

show abstract

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

Cited by 7 publications

References 31 publications

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Comparison of Laparoscopy and Laparotomy in the Management of Early-stage Ovarian Cancer

Contact Info

Product

Resources

About